A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

• Hlavní autoři: Griffin M Pamela (Autor), Abarca Katia (Autor), Trenholme Adrian (Autor), Fernández Pilar (Autor), Hultquist Micki (Autor), Harris Brian (Autor), Losonsky Genevieve A (Autor)
• Médium: Kniha
• Vydáno: BMC, 2010-06-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

<p>Abstract</p> <p>Background</p> <p>Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a humanized RSV monoclo...